Announcements Trials
Browse Landscape

Phase

Phase 1 35Phase 2 12Phase 1/2 5Phase 4 3Phase 3 3Phase NA 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 14Breast 13Gastrointestinal 11Genitourinary 8Head & Neck 6Tumor-Agnostic 1Gynecologic 1

Conditions

Adenocarcinoma 1

Interventions

Oxaliplatin 3cabazitaxel 2Radiation 2Pemetrexed 2Cisplatin 2vinflunine 1vedolizumab 1sugemalimab 1pembrolizumab 1osimertinib 1nedaplatin 1lanreotide 1jinfukang 1enzalutamide 1empagliflozin 1coenzyme Q10 1camrelizumab 1beta-Glucans 1apatinib 1abiraterone 1Waiting Lists 1Tyrosine Kinase Inhibitors 1Surgical Procedures, Operative 1Starch 1Standard of Care 1Sodium Chloride 1Sevoflurane 1Saline Solution, Hypertonic 1Saline Solution 1S 1 (combination) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Docetaxel × Tumor-Agnostic × Clear all
NCT01523015 2013-02-05

Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction

Medical University of Lublin

Phase 2/3 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡